4-(1H-indazol-3-ylamino)-2-isopropyl-2H-phthalazin-1-one | 1272990-64-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(1H-indazol-3-ylamino)-2-isopropyl-2H-phthalazin-1-one
• 英文别名: 4-(1H-indazol-3-ylamino)-2-propan-2-ylphthalazin-1-one
• CAS: 1272990-64-3
• 化学式: C₁₈H₁₇N₅O
• 分子量: 319.366
• InChiKey: MDZQSSAVANPPFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  73.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  邻苯二甲酰肼 在 tris-(dibenzylideneacetone)dipalladium(0) 、 五溴化磷 、 sodium hydride 、 2-(二叔丁基膦)联苯 、 sodium t-butanolate 作用下， 以 乙醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 70.5h， 生成 4-(1H-indazol-3-ylamino)-2-isopropyl-2H-phthalazin-1-one
  参考文献：
  名称：

  Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase

  摘要：

  The inhibition of Aurora kinases in order to arrest mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells has generated significant discussion within the literature. We report a novel class of Aurora kinase inhibitors based upon a phthalazinone pyrazole scaffold. The development of the phthalazinone template resulted in a potent Aurora-A selective series of compounds (typically >1000-fold selectivity over Aurora-B) that display good pharmacological profiles with significantly improved oral bioavailability compared to the well studied Aurora inhibitor VX-680.

  DOI：

  10.1021/jm101346r

文献信息

• Phthalazinone Pyrazoles as Potent, Selective, and Orally Bioavailable Inhibitors of Aurora-A Kinase
  作者：Michael E. Prime、Stephen M. Courtney、Frederick A. Brookfield、Richard W. Marston、Victoria Walker、Justin Warne、Andrew E. Boyd、Norman A. Kairies、Wolfgang von der Saal、Anja Limberg、Guy Georges、Richard A. Engh、Bernhard Goller、Petra Rueger、Matthias Rueth

  DOI：10.1021/jm101346r

  日期：2011.1.13

  The inhibition of Aurora kinases in order to arrest mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells has generated significant discussion within the literature. We report a novel class of Aurora kinase inhibitors based upon a phthalazinone pyrazole scaffold. The development of the phthalazinone template resulted in a potent Aurora-A selective series of compounds (typically >1000-fold selectivity over Aurora-B) that display good pharmacological profiles with significantly improved oral bioavailability compared to the well studied Aurora inhibitor VX-680.